The company lifted its revenue outlook for the year, saying it now expects revenue to grow as much as 25% in 2026.
Moderna’s stock jumps after biotech raises sales outlook
In short
The biotechnology company updated its forward-looking financial targets, triggering positive movement across its market valuation. Management revealed that annual revenue is projected to expand by as much as 25% by 2026. This newly raised top-line outlook reflects stronger expectations for the company's future commercial results.
Key points
- Upwardly revised financial guidance prompted an immediate positive market reaction for th…: Upwardly revised financial guidance prompted an immediate positive market reaction for the biotechnology firm.
- Long-term operational planning points to projected revenue growth reaching up to 25% by 2…: Long-term operational planning points to projected revenue growth reaching up to 25% by 2026.
- Leadership expectations reflect an accelerating financial trajectory over the next severa…: Leadership expectations reflect an accelerating financial trajectory over the next several years.